‘120 pages of da­ta’: Roche’s pipeline re­view leads to as­set cuts, but al­so ad­di­tions

Roche dis­closed on Wednes­day it had cut sev­er­al ear­ly- to mid-stage can­di­dates af­ter a broad­er R&D re­view, which al­so saw pipeline ad­di­tions and trig­gered re­cent­ly-an­nounced ac­qui­si­tions and part­ner­ships.

Dur­ing the com­pa­ny’s pipeline eval­u­a­tion, dubbed the R&D Ex­cel­lence ini­tia­tive, its re­searchers were clear on what the most promis­ing mol­e­cules are based on “120 pages of da­ta,” CEO Thomas Schi­neck­er said dur­ing a me­dia call, adding that it had made de­ci­sions in the third quar­ter of last year. “So, what’s the dead horse that we are rid­ing that we should stop… if you do every­thing at the same speed, you’re not go­ing to be fast,” he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER